Candel Therapeutics, Inc. CADL Accrued Liabilities, Current
Accrued Liabilities, Current at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s accrued liabilities, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s accrued liabilities, current?
- Candel Therapeutics, Inc. (CADL) reported accrued liabilities, current of $3.47M in Q1 2026.
- How has Candel Therapeutics, Inc.'s accrued liabilities, current changed year-over-year?
- Candel Therapeutics, Inc.'s accrued liabilities, current increased by 27.7% year-over-year, from $2.72M to $3.47M.
- What is the long-term trend for Candel Therapeutics, Inc.'s accrued liabilities, current?
- Over 5 years (2020 to 2025), Candel Therapeutics, Inc.'s accrued liabilities, current has grown at a 18.5% compound annual growth rate (CAGR), from $3.14M to $7.33M.